During Thursday’s Current trade, Shares of Qunar Cayman Islands Ltd (NASDAQ:QUNR), lost -1.83% to $41.25.
Qunar Cayman Islands Limited (QUNR) declared that it has received the final judgment (the “Final Judgment”) from the Beijing High People’s Court (the “Court”) with respect to the contract dispute regarding an Inventory Distribution Agreement for hotels with eLong, Inc., which was formerly described in the Company’s annual report on Form 20-F for the fiscal year of 2014. The Company does not believe that the Final Judgment will have any material impact on its future business, results of operations or financial condition.
In the Final Judgment, the Court upheld the prior judgment of the Beijing No. 1 Intermediate People’s Court from January 1, 2015 that (i) our partner, Beijing Qunar Software Technology Co., Ltd. (“Beijing Qunar”) shall credit to the advertisement account opened at Beijing Qunar by eLongNet Information Technology (Beijing) Co., Ltd. (“eLongNet”), a partner of eLong, Inc., the amount of RMB52,335,369 (about US$8.5 million) corresponding to the period up to September 30, 2014; and RMB36,450,000 (about US$6.0 million) for the period from October 1, 2014 through June 30, 2015; (ii) eLongNet shall pay Beijing Qunar a commission of RMB8,127,400 (about US$1.3 million) due under the Inventory Distribution Agreement; and (iii) the Inventory Distribution Agreement shall continue to be performed by both parties. The Court also ordered Beijing Qunar to pay eLongNet RMB227,599 (US$37 thousand) in legal fees, and apportioned court fees between the parties.
Qunar Cayman Islands Limited operates an online travel commerce platform in the People’s Republic of China. The company through its platform provides a range of travel products comprising flight tickets, hotels, vacation packages, and attraction tickets, in addition to display advertising, train tickets, car services, smart lodging, and other services. Its customers comprise flight travel service providers, airlines, independent hotels, online travel agencies, insurance service providers, and others.
Shares of Epizyme Inc (NASDAQ:EPZM), declined -2.02% to $22.8, during its current trading session.
Epizyme Inc (EPZM) a clinical stage biopharmaceutical company creating novel epigenetic therapeutics for cancer patients, recently stated results from the ongoing phase 1 trial of tazemetostat (EPZ-6438), a first-in-class EZH2 inhibitor, showing meaningful clinical activity when used as an oral monotherapy in patients with advanced B-cell non-Hodgkin lymphomas (NHL) and solid tumors. In NHL, treatment with tazemetostat continues to demonstrate an encouraging profile with nine of 15 evaluable NHL patients achieving an objective response, counting a partial response in the first treated patient with an EZH2 tumor mutation. The data, which comprise patients from the dose escalation and dose expansion cohorts of the phase 1 study, in addition to a food effects sub-study, were presented recently by Vincent Ribrag, M.D., Institut Gustave Roussy, at the 13th International Conference on Malignant Lymphoma.
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies for cancer patients. Its proprietary product platform creates small molecule inhibitors of a 96-member class of enzymes known as histone methyltransferases (HMTs). The company has two HMTs inhibitors in clinical development for the treatment of patients with cancers. It is conducting a Phase I/II clinical trial of EPZ-6438, an inhibitor that targets the EZH2 HMT for the treatment of non-Hodgkin lymphoma and advanced solid tumors, counting INI1-deficient tumors, such as synovial sarcoma and malignant rhabdoid tumors; and two Phase 1 clinical trials of EPZ-5676, an inhibitor targeting the DOT1L HMT for the treatment of acute leukemia with genetic alterations of the MLL gene.
Alkermes Plc (NASDAQ:ALKS), during its Thursday’s current trading session decreased -1.20% to $63.99.
Alkermes plc (ALKS) declared the publication of results from its phase 3 clinical trial of aripiprazole lauroxil for the treatment of schizophrenia in the Journal of Clinical Psychiatry. Data from the trial showed that multiple dose strengths of aripiprazole lauroxil administered once monthly demonstrated statistically noteworthy reductions in schizophrenia symptoms, contrast to placebo. Aripiprazole lauroxil is an investigational, novel, long-acting injectable atypical antipsychotic for the treatment of schizophrenia designed to offer patients an alternative to oral antipsychotic medicines that must be taken daily. Aripiprazole lauroxil was developed based on Alkermes’ proprietary LinkeRx® technology and is designed to provide dosing flexibility to address the unique needs of patients with schizophrenia. Once in the body, aripiprazole lauroxil converts to aripiprazole, a molecule that is commercially accessible under the name ABILIFY®. Results of the study served as the basis for Alkermes’ New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) to gain marketing approval of aripiprazole lauroxil for the treatment of schizophrenia, with a regulatory action date of Aug. 22, 2015.
Alkermes Public Limited Company, an integrated biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in various therapeutic areas. The company offers RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA to treat schizophrenia schizoaffective disorder; AMPYRA/FAMPYRA to treat multiple sclerosis; BYDUREON to treat type II diabetes; and VIVITROL for alcohol and opioid dependence. It is also developing Aripiprazole Lauroxil for the treatment of schizophrenia; ALKS 5461 that is under Phase III study for the treatment of depressive disorder; ALKS 3831, a Phase II study medicine to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is under Phase I study to treat multiple sclerosis; ALKS 7106, a drug candidate to treat pain with intrinsically low potential for abuse and overdose death; and RDB 1419, a proprietary investigational biologic cancer immunotherapy product that is under pre-clinical stage
Finally, Vanda Pharmaceuticals Inc. (NASDAQ:VNDA), decreased -0.24%, to $12.52.
Vanda Pharmaceuticals Inc. (Vanda) (VNDA) declared that a HETLIOZ® patent, number 9,060,995 (‘995 patent), is now listed in the U.S. Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book. The ‘995 patent was issued by the United States Patent and Trademark Office on June 23rd, 2015 and expires in January 2033. Prior to this newly listed ‘995 patent, the HETLIOZ® Orange Book listed patents were the U.S. composition of matter ‘529 patent and the ‘492 patent, predictable to expire in December 2022 (assuming receipt of the five year patent term extension under the Hatch-Waxman Act) and January 2033, respectively.
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The companys products comprise HETLIOZ, a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt, a product for the treatment of schizophrenia. Its products also comprise Tradipitant, a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis; Trichostatin A, a small molecule histone deacetylase inhibitor; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
